Gastric Disease
Gastric Disease(胃病)
Gastric Disease 相关产品(92)
- GC49876Pantoprazole N-oxideCAS: 953787-60-5纯度: >95.00%
A potential impurity found in bulk preparations of pantoprazole
- GC52119Lansoprazole sulfone N-oxideCAS: 953787-54-7纯度: >98.00%
A potential impurity found in commercial preparations of lansoprazole
- GC52283L-Cysteine-15N-d3CAS: 1795787-05-1纯度: >99.00%
An internal standard for the quantification of L-cysteine
- GC52384NFAT Inhibitor (cell-permeable) (trifluoroacetate salt)纯度: >95.00%
A cell-permeable form of NFAT inhibitor
- GC524135-Aminosalicylic Acid-d7纯度: >99.00%
An internal standard for the quantification of 5-aminosalicylic acid
- GC91406UK 122 (trifluoroacetate salt)CAS: 1186653-73-5纯度: >95.00%
UK 122是一种尿激酶型纤溶酶原激活剂（uPA）抑制剂（IC50 = 0.2 uM）。它选择性地作用于uPA，而不影响组织型纤溶酶原激活剂（tPA）、胰蛋白酶、纤溶酶和凝血酶（所有的IC50均大于100uM）。
- GC91909Fenoprofen-13C6 (sodium salt hydrate)CAS: 2687960-29-6纯度: >98.00%
Fenoprofen-13C6 (sodium salt hydrate)旨在用作通过GC或LC-MS定量非诺洛芬的内标。
- GC91985Alloisolithocholic Acid-d4CAS: 2410277-60-8纯度: >99.00%
Alloisolithocholic Acid-d4用于GC-或LC-MS定量别异石胆酸的内标。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC49780 | Omeprazole N-oxide | 176219-04-8 | >98.00% | |
A metabolite of omeprazole | ||||
| GC49849 | 3-Aminosalicylic Acid | 570-23-0 | >98.00% | |
A salicylic acid derivative | ||||
| GC49876 | Pantoprazole N-oxide | 953787-60-5 | >95.00% | |
A potential impurity found in bulk preparations of pantoprazole | ||||
| GC52119 | Lansoprazole sulfone N-oxide | 953787-54-7 | >98.00% | |
A potential impurity found in commercial preparations of lansoprazole | ||||
| GC52133 | 12-Tridecenoic Acid | 6006-06-0 | >95.00% | |
A monounsaturated fatty acid | ||||
| GC52180 | WAY-169916 | 669764-18-5 | >98.00% | |
A pathway-selective estrogen receptor ligand | ||||
| GC52283 | L-Cysteine-15N-d3 | 1795787-05-1 | >99.00% | |
An internal standard for the quantification of L-cysteine | ||||
| GC52378 | Cecropin A (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52384 | NFAT Inhibitor (cell-permeable) (trifluoroacetate salt) | - | >95.00% | |
A cell-permeable form of NFAT inhibitor | ||||
| GC52413 | 5-Aminosalicylic Acid-d7 | - | >99.00% | |
An internal standard for the quantification of 5-aminosalicylic acid | ||||
| GC90630 | CRAMP (140-173) (mouse) (trifluoroacetate salt) | - | >98.00% | |
一种抗微生物肽。 | ||||
| GC90701 | CAY10795 | 2241676-74-2 | >98.00% | |
一种15-PGDH抑制剂 | ||||
| GC91083 | Tiopronin-Cysteine Disulfide | 77591-18-5 | >95.00% | |
一种硫普罗宁的代谢产物。 | ||||
| GC91406 | UK 122 (trifluoroacetate salt) | 1186653-73-5 | >95.00% | |
UK 122是一种尿激酶型纤溶酶原激活剂（uPA）抑制剂（IC50 = 0.2 uM）。它选择性地作用于uPA，而不影响组织型纤溶酶原激活剂（tPA）、胰蛋白酶、纤溶酶和凝血酶（所有的IC50均大于100uM）。 | ||||
| GC91449 | Ipamorelin (acetate) | - | >98.00% | |
Ipamorelin是一种五肽生长激素分泌素（GHS）和GHS受体1a（GHS-R1a）激动剂。 | ||||
| GC91909 | Fenoprofen-13C6 (sodium salt hydrate) | 2687960-29-6 | >98.00% | |
Fenoprofen-13C6 (sodium salt hydrate)旨在用作通过GC或LC-MS定量非诺洛芬的内标。 | ||||
| GC91913 | NS 3861 | 216853-59-7 | >98.00% | |
NS 3861是一种神经元烟碱型乙酰胆碱受体（nAChR）激动剂。 | ||||
| GC91985 | Alloisolithocholic Acid-d4 | 2410277-60-8 | >99.00% | |
Alloisolithocholic Acid-d4用于GC-或LC-MS定量别异石胆酸的内标。 | ||||
| GC91986 | Allolithocholic Acid-d4 | - | >99.00% | |
Allolithocholic Acid-d4旨在用作GC或LC-MS定量异石胆酸的内标。 | ||||
| GC92130 | Elsiglutide (acetate) | - | >95.00% | |
Elsiglutide (acetate)是胰高血糖素样肽2 GLP-2的肽衍生物。 | ||||